Big and small news client April 16 news (YMG all-media big and small news reporter Li Junling correspondent Wang Chaoxia Liu Zhengyi) new crown virus vaccination, is the current epidemic prevention and control of the top priority. The reporter just learned from the Yantai Municipal Center for Disease Control and Prevention that a new technology route developed a "recombinant new coronavirus vaccine (CHO cell)" arrived in Yantai on April 16, the whole process of 3 doses, after the completion of vaccination 97% can produce neutralizing antibodies.
It is understood that there are 3 kinds of new coronavirus vaccines in our city, namely 2 new coronavirus inactivated vaccines (Vero cells) produced by Sinopharm Zhongsheng Beijing Company and Beijing Kexing Zhongwei Company, and the recombinant new coronavirus vaccine (CHO cells) produced by Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. These 3 new crown vaccines have good safety, stability and effectiveness, and can be vaccinated with confidence. Regarding the vaccine-related situation, experts from the Municipal Center for Disease Control and Prevention gave detailed answers.
What is a recombinant subunit vaccine?
The recombinant new coronavirus vaccine (CHO cell) is a recombinant subunit vaccine, also known as a recombinant protein vaccine, jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Zhifeilong Kema Company. The principle is that the most effective antigen components are expressed in cells in vitro through genetic engineering methods, and finally made into vaccines. Its technical principle is similar to that of the well-established hepatitis B CHO vaccine. The entire production process is the process of protein expression and purification, without the participation of live viruses, so the production process is safe and easy to produce on a large scale. Vaccines are refrigerated at 2-8 °C, with low requirements for transport and storage conditions.
What is the safety and efficacy of recombinant subunit vaccines?
The vaccine has been reviewed and approved by the drug regulatory authorities, and its safety and effectiveness have been guaranteed.
Safety: The safety of the recombinant subunit vaccine is good, most of the subjects have no adverse reactions, and a very small number of subjects may have pain, redness or induration at the vaccination site, as well as clinical manifestations such as fever, fatigue, nausea, headache, muscle soreness, etc., which can basically resolve within 1-3 days.
Effectiveness: After 2 doses of this vaccine, 76% can produce neutralizing antibodies; after 3 doses, 97% can produce neutralizing antibodies, and the antibody level is higher, which can reach 2 times the amount of serum antibodies in recovered patients.
Who is the inoculated? What is the vaccination procedure?
The target of vaccination is 18 years of age and older without contraindications to vaccination. A total of 3 doses are given throughout the course, and the interval between adjacent 2 doses is recommended ≥ 4 weeks. The second dose should be completed as soon as possible within 8 weeks after the first dose. The 3rd dose should be completed as soon as possible within 6 months after the first dose. The site of inoculation is intramuscular injection of the deltoid muscle of the upper arm.
What are the contraindications to vaccination?
(1) Those who are known to be allergic to any component of the vaccine, including excipients.
(2) Those suffering from acute diseases, serious chronic diseases, acute onset of chronic diseases and fever.
(3) Pregnant women.
(4) Patients with uncontrolled epilepsy and other progressive nervous system diseases.
Can inactivated vaccine products be interchanged?
According to the Technical Guidelines for COVID-19 Vaccination (First Edition), in case of special circumstances, when the full vaccination of the new coronavirus vaccine of the same enterprise cannot be completed, the same type of vaccine of other enterprises can be used to complete the vaccination.
Therefore, if the inactivated vaccine is vaccinated, the second dose can use the inactivated vaccine of another manufacturer. For those who receive recombinant subunit vaccines, because there is only one product in the domestic production process, the follow-up two injections can only be vaccinated with the same type of vaccine, and cannot be replaced by inactivated vaccines.
Which vaccine is more effective? Can individuals choose different brands of vaccines?
At present, China has three types of technical routes and 5 new coronavirus vaccines have been approved for use: one is inactivated vaccine, the second is adenovirus vector vaccine, and the third is a recombinant subunit vaccine. These new coronavirus vaccines have been reviewed and approved by the drug regulatory authorities, which are safe and effective, and can be vaccinated with confidence.
Vaccines are uniformly allocated by the state, medical insurance bears the cost of vaccines, and the masses are vaccinated free of charge. Vaccine varieties can not be independently selected for the time being, in order to form a population-wide immune barrier as soon as possible, do not hesitate, do not have to wait, in time to your local vaccination site vaccination, as soon as possible vaccination, as soon as possible to get protection.
How can people who have not completed the full immunization program be revaccinated? Need to start over?
Disease control experts said that those who have not completed the full vaccination should re-inject the incomplete dose as soon as possible and do not need to start the vaccination again.
Editor-in-Charge: Yang Yunge